Developing a broadly protective influenza vaccine with transmission blocking efficacy.

£2,300,738 / June 2024

Leading virus species identification and analysis for the New York City Virus Hunters community science program.

$1,073,042 / May 2024

Incorporating genotype accessibility into influenza virus evolutionary predictions.

$1,370,388 / May 2024

Equips schools and education stakeholders with information and guidance to improve ventilation and air filtration in classrooms.

$955,710 / May 2024, October 2021, August 2021

To advance the development of Respiratory Scout, a low-cost molecular test to diagnose influenza and other respiratory virus infections.

$161,000 / March 2024

Establishing FluGuardians, a new birth cohort study to gain a deeper understanding of the development of influenza immunity.

$6,663,637 / March 2024

• Conducting far-UVC light ocular and stratum corneum safety studies in diverse human populations.

• $1,662,490 / March 2024

Evaluating the immunogenicity and protection of an intranasal universal influenza vaccine candidate against wild-type transmission in ferrets.

$406,000 / December 2023

Creating a handheld, rapid result, breath-based diagnostic for the detection of multiple respiratory pathogens.

$3,595,280 / November 2023

Developing inhalable, broad-spectrum antivirals that provide extended prophylaxis against infectious diseases.

$159,000 / October 2023

Creating the first universal testing platform to provide fast, accurate, digital imaging-based identification for infectious disease pathogens.

Seed / October 2023

Investigating, in ferrets against H3N2, the sterilizing immunity potential of an intranasal universal influenza vaccine construct.

$59,215 / July 2023

• Adapting graphene-based biosensors for the selective detection of influenza.

• $1,348,454 / June 2023

Establishing a reproducible, experimental human infection model of influenza virus transmission and evaluating interventions.

$3,479,305 / March 2023

Evaluating treatments for severe and complicated influenza infections in hospitalized patients with RECOVERY FLU, a cost-efficient, adaptive platform clinical trial.

£11,416,263 / December 2022

Establishing a swine herd model for assessing the efficacy of broadly protective influenza virus vaccines.

$839,646 / December 2022

Leads a multidisciplinary and collaborative effort to observe and examine the reintroduction and transmission of influenza in New Zealand and identify novel immunological markers to inform influenza vaccine development.

11,340,572 NZD / December 2022, May 2021

Developing fast, accurate, and affordable molecular tests for routine use by everyone, including consumers in the home, employees in the workplace, and students at school.

Series C / November 2022, Series B / April 2021

Leads INVITED, a multicenter, prospective randomized clinical trial among Type 1 diabetes patients to improve our understanding of the protective effect of influenza vaccination.

2,382,555 DKK / October 2022

Reducing barriers to better treatments by designing and delivering high-quality, large-scale and global clinical trials at a fraction of current industry cost.

£5,000,000 / October 2022

Creates an immersive approach to science education to unlock the potential of the next generation of influenza researchers in New York City.

$1,146,303 / July 2022, April 2020

Leverages the expertise of over 100 behavioral scientists to identify effective, scalable interventions for promoting immunizations.

$2,435,763 / March 2022, June 2021, October 2020

Leads the Multidisciplinary InvesTIGAtion of Transmission to Ease inFLUenza (MITIGATE FLU) study to transform our understanding of influenza virus transmission.

$8,792,291 / February 2022

Optimizing ventilation system operations to minimize airborne infectious disease transmission, pollutant exposure, and energy consumption.

$327,539 / November 2021

Leads multiple initiatives to promote open science and expand the publication of null and negative influenza research findings and replication studies.

$18,398,983 / August 2021, April 2020, August 2019

Brings diverse thinkers and disciplines together to identify big ideas and promote pathways to accelerating universal influenza vaccine development.

$8,900,000 / June 2021, January 2018

Pursuing a novel, host-directed approach to a universal influenza vaccine.

$904,384 / June 2021

Brought together immunization managers and school nurses to identify replicable best practices for school-located vaccination programs.

$208,035 / June 2021

Supports eight teams developing novel, transformative approaches to universal influenza vaccines (in partnership with the Bill & Melinda Gates Foundation)

$6,215,453 / April 2021, January 2021, August 2019

Leads a research agenda centered on influenza transmission and the interplay between influenza and SARS-CoV-2 viruses.

$2,539,000 / March 2021

Develops ultra-sensitive genomic and CRISPR technologies to detect pathogens in multiple, connected settings to prevent pandemics before they start.

$5,000,000 / February 2021

Combines diagnostic technology and information-sharing platforms to connect early warning data to the public health community.

$11,250,000 / December 2020

Assessing performance characteristics and market dynamics of universal influenza vaccines using mathematical modeling methods.

$381,199 / November 2020

Demonstrated the utility of wearables for early disease signaling, before symptoms emerge.

$1,870,000 / October 2020, August 2020

Provides a crowdsourced infectious disease surveillance system to provide early outbreak warnings for communities and local public health agencies.

$1,005,451 / August 2020

Developed and examined a novel strategy for disease surveillance that improves representativeness of population samples.

$230,000 / August 2020

Evaluated the direct and indirect health impacts of a school-based seasonal influenza vaccination program in the Bay Area.

$278,422 / August 2020, February 2020, February 2019

Created an open source, anonymous, privacy-first symptom sharing and exposure alerting application to help communities of close contacts protect themselves.

$100,000 / May 2020

Offers an inexpensive, self-contained, and scalable mRNA manufacturing platform for vaccines targeting infectious diseases, including influenza and COVID-19.

Special purpose funding round / May 2020 (Exited)